DCGI gives nod to Serum Institute to restart phase 2,3 trials for COVID-19 vaccine
DCGI gives nod to Serum Institute to restart phase 2,3 trials for COVID-19 vaccine
newKerala.com
0 shares
1 views
You might like
Related news coverage
Mumbai: Clinical trial of COVID-19 vaccine begins at KEM, Nair hospitals
Mid-Day
Three candidates in the age group of 25 to 45 were given the first trial dose of COVID-19 vaccine, developed by the Oxford..
-
Can Centre procure Rs 80,000 crore to buy, distribute COVID-19 vaccine across India? SII CEO Adar Poonawalla
DNA
-
Can Centre procure Rs 80,000 crore to buy, distribute COVID-19 vaccine across India? SII CEO Adar Poonawalla asks
DNA
-
Mumbai: KEM hospital gets gets nod for COVID-19 vaccine trials
Mid-Day
-
Serum Institute of India gets DCGI nod to resume clinical trial of Oxford COVID-19 vaccine
Mid-Day
Advertisement
More coverage
Serum Institute of India gets DCGI permission to restart phase 2, 3 trials of coronavirus COVID-19 vaccine
Zee News
The Serum Institute of India (SII) is all set to restart its phase two and three clinical trials for the COVID-19 vaccine after..
-
Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod
DNA
-
Serum Institute of India gets DCGI nod to resume clinical trial of Oxford Covid-19 vaccine
IndiaTimes
-
COVID-19: India did not have huge peak at all, says ICMR DG
Mid-Day
-
Serum Institute to resume vaccine trials after DCGI nod
IndiaTimes